Cost effectiveness assessments should be more widely used as a way to wrangle rising drug prices, the author of a recent opinion piece published in The Inquirer writes.
Using cost effectiveness is one solution that could help cut drug prices without creating conflict with the pharmaceutical industry.
“At a time when much of the country recognizes the importance of reducing out-of-control drug costs, the industry might find this to be the most acceptable way to achieve that end,” the author, pediatric cardiologist Arthur Garson Jr., writes.
To read more on The Inquirer, click here.
